Acción TAK TAKEDA PHARMACEUTICAL COMPANY LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Takeda Pharmaceutical Company Limited Nyse

Acciones

TAK

US8740602052

Mercado cerrado - Nyse
Otros sitios de cotización
 22:00:02 25/06/2024 		Varia. Cinco días. Varia. 1 de enero.
12,98 USD +0,78 % Gráfico intradía de Takeda Pharmaceutical Company Limited +2,45 % -9,04 %
25/06 Los CDC de EE.UU. alertan a los profesionales sanitarios del aumento de casos de dengue RE
25/06 Un fármaco contra el cáncer de Takeda obtiene la aprobación de la Comisión Europea MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Takeda Announces New Assignments of Directors
US CDC alerts healthcare providers of increase in dengue cases
Takeda's Cancer Drug Gets European Commission Approval
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
Les sorcières épouvantent l'IA
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 4502
  4. Acción TAK
  5. Noticias Takeda Pharmaceutical Company Limited
  6. Otros idiomas